Indication
Pulmonary Fibrosis Interstitial
2 clinical trials
2 products
Clinical trial
A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung DiseaseStatus: Terminated, Estimated PCD: 2024-02-23
Product
IxazomibClinical trial
Impact of Colchicine on the Clinical Outcome of COVID-19 and the Development of Post-COVID-19 Pulmonary Fibrosis: Randomized Controlled Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2021-08-25
Product
Colchicine